Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228525 · ClinicalTrials.gov registry record · Phase 2
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02228525: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02228525 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02228525, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.
Interventions
- DRUG selinexor (KPT-330)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-08-27 |
| Est. Completion | 2021-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228525
The ClinicalTrials.gov registry entry for NCT02228525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which selinexor (KPT-330) is the first listed.
NCT02228525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228525 about?
NCT02228525 is a clinical study titled "Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes". The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.
What is the current status of trial NCT02228525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2014-08-27. Estimated completion is 2021-04-06.
What interventions are being tested in trial NCT02228525?
The interventions under investigation include: selinexor (KPT-330) (DRUG).
Who is sponsoring clinical trial NCT02228525?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.